{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:26:45Z","timestamp":1790796405095,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["82073909"],"award-info":[{"award-number":["82073909"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["81973378"],"award-info":[{"award-number":["81973378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010010","name":"Shanxi Province Science Foundation for Youths","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopha.2024.117202","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T17:02:10Z","timestamp":1721840530000},"page":"117202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["GLP-1R mediates idebenone-reduced blood glucose in mice"],"prefix":"10.1016","volume":"178","author":[{"given":"Xin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Bin Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0305-3127","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2826-5804","authenticated-orcid":false,"given":"Yunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117202_bib1","first-page":"1","article-title":"The predicted mechanisms and evidence of probiotics on type 2 diabetes mellitus (T2DM)","author":"Bajinka","year":"2023","journal-title":"Arch. Physiol. Biochem"},{"key":"10.1016\/j.biopha.2024.117202_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2023.112029","article-title":"Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion","volume":"577","author":"Shang","year":"2023","journal-title":"Mol. Cell Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117202_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.biopha.2024.117202_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2024.117202_bib5","article-title":"Novel small molecule glucagon-like peptide-1 receptor agonist S6 stimulates insulin secretion from rat islets","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharm."},{"issue":"15","key":"10.1016\/j.biopha.2024.117202_bib6","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jama.2019.2941","article-title":"The future of the GLP-1 receptor agonists","volume":"321","author":"Hirsch","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.biopha.2024.117202_bib7","first-page":"146","article-title":"New drug for type 2 diabetes: introduction of oral semaglutide (Rybelsus\u00ae tablets), an oral GLP-1 receptor agonist]. Nihon Yakurigaku Zasshi","volume":"157","author":"Miyasaka","year":"2022"},{"key":"10.1016\/j.biopha.2024.117202_bib8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2147\/DDDT.S404055","article-title":"Cinchonine, a potential oral small-molecule glucagon-like peptide-1 receptor agonist, lowers blood glucose and ameliorates non-alcoholic steatohepatitis","volume":"17","author":"Xue","year":"2023","journal-title":"Drug Des. Devel Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117202_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5795","key":"10.1016\/j.biopha.2024.117202_bib10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.biopha.2024.117202_bib11","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.3390\/ijms20225601","article-title":"Cellular stress-modulating drugs can potentially be identified by in silico screening with Connectivity Map (CMap)","volume":"20","author":"Gao","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.117202_bib12","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.jpedsurg.2018.02.060","article-title":"Gene expression profiling coupled with Connectivity Map database mining reveals potential therapeutic drugs for Hirschsprung disease","volume":"53","author":"Xiao","year":"2018","journal-title":"J. Pedia Surg."},{"issue":"3","key":"10.1016\/j.biopha.2024.117202_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0229-z","article-title":"Connectivity map identifies luteolin as a treatment option of ischemic stroke by inhibiting MMP9 and activation of the PI3K\/Akt signaling pathway","volume":"51","author":"Luo","year":"2019","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.biopha.2024.117202_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1017832","article-title":"Identification of small molecules as novel anti-adipogenic compounds based on Connectivity Map","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2024.117202_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fncel.2018.00529","article-title":"Idebenone alleviates neuroinflammation and modulates microglial polarization in LPS-Stimulated BV2 Cells and MPTP-induced parkinson's disease mice","volume":"12","author":"Yan","year":"2019","journal-title":"Front Cell Neurosci."},{"issue":"9","key":"10.1016\/j.biopha.2024.117202_bib16","first-page":"938","article-title":"Idebenone decreases A\u03b2 pathology by modulating RAGE\/Caspase-3 signaling and the A\u03b2 degradation enzyme NEP in a mouse model of AD","volume":"10","author":"Lee","year":"2021","journal-title":"Biol. (Basel)"},{"key":"10.1016\/j.biopha.2024.117202_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8548380","article-title":"Idebenone-activating autophagic degradation of \u03b1-synuclein via inhibition of AKT-mTOR pathway in a SH-SY5Y-A53T model of parkinson's disease: a network pharmacological approach","volume":"2021","author":"He","year":"2021","journal-title":"Evid. Based Complement Altern. Med"},{"key":"10.1016\/j.biopha.2024.117202_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.phrs.2018.12.008","article-title":"Idebenone and T2D: a new insulin-sensitizing drug for personalized therapy","volume":"139","author":"Dassano","year":"2019","journal-title":"Pharm. Res"},{"issue":"10","key":"10.1016\/j.biopha.2024.117202_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22876","article-title":"Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice","volume":"35","author":"Jiang","year":"2021","journal-title":"J. Biochem Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117202_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40530-w","article-title":"Identification of immune infiltration-related biomarkers in carotid atherosclerotic plaques","volume":"13","author":"Zheng","year":"2023","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2024.117202_bib21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/cells8111325","article-title":"Co-translational insertion of aquaporins into liposome for functional analysis via an E. coli based cell-free protein synthesis system","volume":"8","author":"Yue","year":"2019","journal-title":"Cells"},{"issue":"144","key":"10.1016\/j.biopha.2024.117202_bib22","doi-asserted-by":"crossref","DOI":"10.3791\/58882","article-title":"Escherichia coli-based cell-free protein synthesis: protocols for a robust, flexible, and accessible platform technology","author":"Levine","year":"2019","journal-title":"J. Vis. Exp."},{"issue":"5","key":"10.1016\/j.biopha.2024.117202_bib23","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00253-007-1230-3","article-title":"Cloning, stable expression of human phosphodiesterase 7A and development of an assay for screening of PDE7 selective inhibitors","volume":"77","author":"Malik","year":"2008","journal-title":"Appl. Microbiol Biotechnol."},{"key":"10.1016\/j.biopha.2024.117202_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.phrs.2018.09.024","article-title":"Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition","volume":"137","author":"Tomilov","year":"2018","journal-title":"Pharm. Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.117202_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11064-020-03186-w","article-title":"Idebenone ameliorates rotenone-induced parkinson's disease in rats through decreasing lipid peroxidation","volume":"46","author":"Avc\u0131","year":"2021","journal-title":"Neurochem Res"},{"issue":"6","key":"10.1016\/j.biopha.2024.117202_bib26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10557-020-07018-5","article-title":"Idebenone protects against atherosclerosis in apolipoprotein E-Deficient mice via activation of the SIRT3-SOD2-mtROS pathway","volume":"35","author":"Jiang","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.biopha.2024.117202_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpba.2012.10.008","article-title":"Application of Bio-Layer Interferometry for the analysis of protein\/liposome interactions","volume":"72","author":"Wallner","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6141","key":"10.1016\/j.biopha.2024.117202_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"issue":"45","key":"10.1016\/j.biopha.2024.117202_bib29","doi-asserted-by":"crossref","first-page":"14970","DOI":"10.1021\/jacs.6b08323","article-title":"\u03b2-Arrestin-Biased Agonists of the GLP-1 Receptor from \u03b2-Amino Acid Residue Incorporation into GLP-1 Analogues","volume":"138","author":"Hager","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"8","key":"10.1016\/j.biopha.2024.117202_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.molmet.2014.08.001","article-title":"CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse \u03b2-cells","volume":"3","author":"Shin","year":"2014","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2024.117202_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.23736\/S0031-0808.18.03455-9","article-title":"Current therapies and targets for type 2 diabetes mellitus","volume":"60","author":"Chellappan","year":"2018","journal-title":"Panminerva Med"},{"key":"10.1016\/j.biopha.2024.117202_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coph.2016.08.005","article-title":"GLP-1 as a target for therapeutic intervention","volume":"31","author":"Rajeev","year":"2016","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.biopha.2024.117202_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2024.117202_bib34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bph.15485","article-title":"Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands","volume":"179","author":"Tanday","year":"2022","journal-title":"Br. J. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2024.117202_bib35","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1021\/acs.jmedchem.9b01071","article-title":"Design, synthesis, and pharmacological evaluation of potent positive allosteric modulators of the glucagon-like peptide-1 receptor (GLP-1R)","volume":"63","author":"M\u00e9ndez","year":"2020","journal-title":"J. Med Chem."},{"issue":"3","key":"10.1016\/j.biopha.2024.117202_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.biopha.2024.117202_bib37","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its glass B G protein-coupled receptors: a long march to therapeutic successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharm. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2024.117202_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MED.0b013e32835edb32","article-title":"GLP-1R agonist therapy for diabetes: benefits and potential risks","volume":"20","author":"Samson","year":"2013","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117202_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/dom.12343","article-title":"Cooperation between cAMP signalling and sulfonylurea in insulin secretion","volume":"16","author":"Shibasaki","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2024.117202_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1874467211104030187","article-title":"Roles and regulation of the transcription factor CREB in pancreatic \u03b2 -cells","volume":"4","author":"Dalle","year":"2011","journal-title":"Curr. Mol. Pharm."},{"issue":"Pt 2)","key":"10.1016\/j.biopha.2024.117202_bib41","article-title":"Achyranthes bidentata polysaccharide ameliorates type 2 diabetes mellitus by gut microbiota-derived short-chain fatty acids-induced activation of the GLP-1\/GLP-1R\/cAMP\/PKA\/CREB\/INS pathway","volume":"270","author":"Xia","year":"2024","journal-title":"Int J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117202_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ijms21020484","article-title":"Idebenone protects against acute murine colitis via antioxidant and anti-inflammatory mechanisms","volume":"21","author":"Sohal","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117202_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175569","article-title":"Idebenone attenuates ferroptosis by inhibiting excessive autophagy via the ROS-AMPK-mTOR pathway to preserve cardiac function after myocardial infarction","volume":"943","author":"Li","year":"2023","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2024.117202_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777395","article-title":"Lipidomic analysis reveals the protection mechanism of GLP-1 analogue dulaglutide on high-fat diet-induced chronic kidney disease in mice","volume":"12","author":"Yeung","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.117202_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6820377","article-title":"Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations","volume":"2022","author":"Xu","year":"2022","journal-title":"Cardiovasc Ther."},{"issue":"11","key":"10.1016\/j.biopha.2024.117202_bib46","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1016\/j.apsb.2022.06.003","article-title":"The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury","volume":"12","author":"Pang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2024.117202_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110823","article-title":"Novel idebenone analogs block Shc's access to insulin receptor to improve insulin sensitivity","volume":"132","author":"Hui","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2024.117202_bib48","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034801","article-title":"Idebenone and coenzyme Q10 are novel PPAR\u03b1\/\u03b3 ligands, with potential for treatment of fatty liver diseases","volume":"11","author":"Tiefenbach","year":"2018","journal-title":"Dis. Model Mech."},{"issue":"3","key":"10.1016\/j.biopha.2024.117202_bib49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/08941939.2021.1898063","article-title":"Protective effects of idebenone against sepsis induced acute lung damage","volume":"35","author":"Akpinar","year":"2022","journal-title":"J. Invest Surg."},{"issue":"6","key":"10.1016\/j.biopha.2024.117202_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147734","article-title":"DNAJC30 biallelic mutations extend mitochondrial complex I-deficient phenotypes to include recessive Leber's hereditary optic neuropathy","volume":"131","author":"Wiggs","year":"2021","journal-title":"J. Clin. Invest"},{"issue":"11","key":"10.1016\/j.biopha.2024.117202_bib51","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5650\/jos.62.961","article-title":"Potential impact of quercetin and idebenone against immuno- inflammatory and oxidative renal damage induced in rats by titanium dioxide nanoparticles toxicity","volume":"62","author":"Al-Rasheed","year":"2013","journal-title":"J. Oleo Sci."},{"issue":"2","key":"10.1016\/j.biopha.2024.117202_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s13340-019-00423-8","article-title":"The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes","volume":"11","author":"Rasmussen","year":"2020","journal-title":"Diabetol. Int"},{"issue":"47","key":"10.1016\/j.biopha.2024.117202_bib53","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2024.117202_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.biopha.2024.117202_bib55","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.biopha.2024.117202_bib56","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2024.117202_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.biopha.2024.117202_bib58","first-page":"CD013720","article-title":"Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline","volume":"12","author":"Garegnani","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2024.117202_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10384-020-00792-7","article-title":"Characteristics of Japanese patients with Leber's hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study","volume":"65","author":"Ishikawa","year":"2021","journal-title":"Jpn J. Ophthalmol."},{"issue":"9979","key":"10.1016\/j.biopha.2024.117202_bib60","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2024.117202_bib61","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/WNO.0000000000001023","article-title":"Real-world clinical experience with idebenone in the treatment of Leber Hereditary Optic Neuropathy","volume":"40","author":"Catarino","year":"2020","journal-title":"J. Neuroophthalmol."},{"issue":"12","key":"10.1016\/j.biopha.2024.117202_bib62","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2024.117202_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117291","article-title":"Design, synthesis, and biological evaluation of a potential long-acting glucagon-like peptide-1 (GLP-1) analog","volume":"85","author":"Zhang","year":"2023","journal-title":"Bioorg. Med Chem."},{"issue":"8","key":"10.1016\/j.biopha.2024.117202_bib64","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1432-2277.2011.01275.x","article-title":"Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts","volume":"24","author":"Tian","year":"2011","journal-title":"Transpl. Int"},{"key":"10.1016\/j.biopha.2024.117202_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:39:32Z","timestamp":1777862372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224010862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":65,"alternative-id":["S0753332224010862"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117202","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1R mediates idebenone-reduced blood glucose in mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117202"}}